Rare diseases are more common than many realize, affecting every 1 in 17 people worldwide. This #RareDiseaseDay, we're reminded that the impact of rare diseases is greater than most can imagine. At Relay Tx, we are committed to advancing research for these unmet needs and improving care for the rare community. 🦓
Relay Therapeutics
生物技术研究
Cambridge，MA 28,107 位关注者
Integrating leading-edge computational and experimental science to transform human health.
关于我们
Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. By applying these insights, we believe we have a differentiated approach to drug protein targets based on their motion, enabling us to select and advance unique product candidates that can be developed into novel therapies for patients. Located in Cambridge, Massachusetts, our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!
- 网站
-
http://www.relaytx.com
Relay Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，MA
- 类型
- 上市公司
- 创立
- 2016
- 领域
- Protein Motion、Allosteric Drug Discovery、Structural Biology、Biophysics、Computation、Chemistry、Cancer Biology和precision oncology
地点
-
主要
获取路线
399 Binney Street
2nd Floor
US，MA，Cambridge，02139
Relay Therapeutics员工
动态
-
Today, in our Q4 and full year 2024 financial results, we highlighted the full trial design of our Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced #breastcancer, which will initiate in mid-2025. Find full details here. https://lnkd.in/esBzRcTj
-
-
Survey data in #metastaticbreastcancer patients show they are just as concerned about quality of life and side effects of medication as they are about their disease progression. Dr. Sarah Sammons MD, a medical oncologist specializing in the care of patients with breast cancer at Dana-Farber and a primary investigator for Relay Tx’s ReDiscover trial, joined the Susan G. Komen Real Pink podcast to discuss the potential of personalized medicine in metastatic breast cancer.
Breast cancer treatment today is becoming more personalized and more precise. Tune into the latest episode of Komen's Real Pink podcast to hear Dr. Sarah Sammons of Dana-Farber Institute explore the exciting new possibilities brought by personalized medicine, including whether it can help slow disease progression and how it can improve patients’ abilities to potentially live more active and productive lives while in treatment. Listen wherever you get your podcasts or https://apple.co/2LMAcsi Thanks to Relay Therapeutics Relay Therapeutics for supporting the Real Pink Podcast.
-
-
Our Director of Biology, Fabien Llambi, will present our differentiated preclinical work in #vascularmalformations at #VAC2025 this week. As we advance our commitment to innovation, we’re preparing to initiate the Phase 1 clinical trial of RLY-2608 in PI3Kα-driven vascular malformations by the end of Q1. This marks a significant milestone in our journey to develop transformative therapies for patients. Congratulations to Fabien and our entire vascular malformations team on this achievement! 🎉
-
-
Eight was great, but nine is divine! Today, we celebrate nine years of innovation, dedication, and impact. A huge thank you to our incredible team of Relayers and the patients, families, and investigators who inspire our mission every day. Here’s to the past, the future, and the lives we strive to change - cheers to 9! 🎂
-
Relay Therapeutics CEO Sanjiv Patel will present at #JPM25 on what's to come this year as we continue to transform the #drugdiscovery landscape. Find more details below. We look forward to connecting in San Francisco!
-
-
𝘛𝘪𝘥𝘪𝘯𝘨𝘴 𝘰𝘧 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺 🎁 This holiday season, Relayers partnered with Happy Hope Factory to assemble activity-filled bundles for children at our local Boston-area hospitals. Each bundle included games related to STEM and the arts, and hopefully lots of 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺, 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺.
-
-
Today, we announced updated data for RLY-2608 + fulvestrant that continue to demonstrate clinically meaningful progression free survival, which will be shared at #SABCS24 today. President of R&D Dr. Donald Bergstrom shares more about the significance of these data below. Tune into our conference call this morning, December 11, at 7:00AM ET for more insight. Learn more here. https://lnkd.in/erSDuRDJ
-
-
We are pleased to announce we will present updated clinical data for RLY-2608 + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic #breastcancer at #SABCS24. We will host a conference call to discuss these data on Wednesday, December 11 at 7:00 a.m. ET. Find more details here. https://lnkd.in/eAH-dQTG
-
-
Today, we're pleased to announce we have entered into an exclusive global licensing agreement with Elevar Therapeutics for lirafugratinib, a highly selective irreversible small-molecule inhibitor of FGFR2, in FGFR2-driven cholangiocarcinoma and other solid tumors. Learn more here. https://lnkd.in/eJ7rfS75
-